Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector

被引:26
|
作者
Fukui, T
Hayashi, Y
Kagami, H
Yamamoto, N
Fukuhara, H
Tohnai, I
Ueda, M
Mizuno, M
Yoshida, J
机构
[1] Nagoya Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Mol Neurosurg, Showa Ku, Nagoya, Aichi 4668550, Japan
[3] Nagoya Univ, Grad Sch Med, Dept Neurosurg, Showa Ku, Nagoya, Aichi 4668550, Japan
来源
ORAL ONCOLOGY | 2001年 / 37卷 / 03期
关键词
squamous cell carcinoma; suicide gene therapy; adeno-associated virus; herpes simplex virus thmidine kinase; ganciclovir;
D O I
10.1016/S1368-8375(00)00093-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to test the possibility of gene transfer as a new therapy for oral cancer. Adeno-associated virus (AAV) has already been used in the fields of cystic fibrosis and Parkinson's disease as a potential vector for gene therapy because of its wide host range, high transduction efficiency, and lack of cytopathogenicity. Four human oral squamous cell carcinoma cell lines were transduced with an AAV vector containing the P-galactosidase gene (AAVlacZ) in vitro. Gene transduction efficiency was from 20 to 50% at a multiplicity of infection (MOI; for the purposes of this study the number of vector genomes per target cell) of 1 x 10(3), and nearly 100% of each cell line were transduced at an MOI of 1 x 10(4). Next, four cell lines were transduced with an AAV vector containing the herpes simplex virus thymidine kinase (HSVtk) gene, which sensitizes transduced cells to ganciclovir (GCV). Subsequent administration of GCV resulted in nearly 100% tumor cell killing at an MOI of 1 x 10(4) and from 70 to 80% tumor cell killing at an MOI of 1 x 10(3). These results suggest that AAV-mediated gene transfer of HSVtk and administration of GCV has potential as a new therapy for oral squamous cell carcinoma. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:211 / 215
页数:5
相关论文
共 50 条
  • [21] Direct gene transfer into human epileptogenic hippocampal tissue with an adeno-associated virus vector: Implications for a gene therapy approach to epilepsy
    Freese, A
    Kaplitt, MG
    OConnor, WM
    Abbey, M
    Langer, D
    Leone, P
    OConnor, MJ
    During, MJ
    EPILEPSIA, 1997, 38 (07) : 759 - 766
  • [22] Characteristics and advantages of adeno-associated virus vector-mediated gene therapy for neurodegenerative diseases
    Yuan Qu
    Yi Liu
    Ahmed Fayyaz Noor
    Johnathan Tran
    Rui Li
    Neural Regeneration Research, 2019, 14 (06) : 931 - 938
  • [23] Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines
    Kotin, Robert M.
    Snyder, Richard O.
    HUMAN GENE THERAPY, 2017, 28 (04) : 350 - 360
  • [24] Characteristics and advantages of adeno-associated virus vector-mediated gene therapy for neurodegenerative diseases
    Qu, Yuan
    Liu, Yi
    Noor, Ahmed Fayyaz
    Tran, Johnathan
    Li, Rui
    NEURAL REGENERATION RESEARCH, 2019, 14 (06) : 931 - 938
  • [25] Hepatic gene therapy using adeno-associated virus vectors
    Patijn, GA
    Kay, MA
    SEMINARS IN LIVER DISEASE, 1999, 19 (01) : 61 - 69
  • [26] Adeno-associated virus (AAV) gene therapy for neurological disease
    Weinberg, Marc S.
    Samulski, R. Jude
    McCown, Thomas J.
    NEUROPHARMACOLOGY, 2013, 69 : 82 - 88
  • [27] Adeno-associated virus vectors for gene therapy of neurodegenerative disorders
    During, MJ
    Leone, P
    CLINICAL NEUROSCIENCE, 1996, 3 (05) : 292 - 300
  • [28] Adeno-associated virus (AAV) vectors in cancer gene therapy
    Santiago-Ortiz, Jorge L.
    Schaffer, David V.
    JOURNAL OF CONTROLLED RELEASE, 2016, 240 : 287 - 301
  • [29] A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy
    Ruan, HJ
    Su, H
    Hu, L
    Lamborn, KR
    Kan, YW
    Deen, DF
    NEOPLASIA, 2001, 3 (03): : 255 - 263
  • [30] Adeno-associated virus-based vectors in gene therapy
    Tal, J
    JOURNAL OF BIOMEDICAL SCIENCE, 2000, 7 (04) : 279 - 291